Clinical Validation of InferRead Lung CT.AI

Completed

Conditions studied: Lung Cancer

In brief

Lung cancer is the second most common cause of cancer-related death in men and women. Early pulmonary nodule screening is an effective means to prevent lung cancer, which is no less important than the diagnosis and treatment of lung cancer. Early lung cancer screening has been investigated and applied as a medical practice. InferRead Lung CT.AI by Infervision is a dedicated post processing application that generates CADe marks as an overlay on the original CT series intended to aid the radiologist in the detection of pulmonary nodules. This study was designed to evaluate radiologists' performance in detecting actionable nodules on chest CT when aided by InferRead.

Key facts

Study ID

NCT04119960

Run by

Infervision

People needed

250

Starts

2019-01-10

Expected to finish

2019-10-30

Last updated by the study team

2020-07-28

Who can join

Age: 55 and older, up to 75. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Lung cancer screening eligible patients

Where it is running

• University of Maryland Medical Center — Baltimore, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.